Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

被引:1
|
作者
Chiang, Ting-Yu [1 ]
Hsu, Hung-Chih [2 ]
Chern, Yih-Jong [3 ]
Liao, Chun-Kai [3 ]
Hsu, Yu-Jen [3 ]
Tsai, Wen-Sy [3 ]
Hsieh, Pao-Shiu [3 ]
Lin, Yu-Fen [1 ]
Lee, Hsiu-Lan [1 ]
You, Jeng-Fu [3 ]
机构
[1] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Nursing, Taoyuan 33305, Taiwan
[2] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Div Hematol Oncol, Taoyuan 33305, Taiwan
[3] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Surg,Div Colon & Rectal Surg, Taoyuan 33305, Taiwan
关键词
metastatic CRC; mCRC; skin toxicity; survival; anti-EGFR; QUALITY-OF-LIFE; PANITUMUMAB; MANAGEMENT; THERAPY; IMPACT; TRIAL;
D O I
10.3390/cancers15061663
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The primary treatment for metastatic colorectal cancer (mCRC) consists of targeted therapy and chemotherapy to improve survival. A molecular target drug with an anti-epidermal growth factor receptor (EGFR) antagonist is recommended when the RAS and BRAF genes are normal. About 50-70% of patients using anti-EGFR antagonists will experience skin reactions. Some studies have shown that severe skin reactions caused by anti-EGFR antagonists may be linked to overall survival (OS) and progression-free survival (PFS), but the results are still uncertain. These data of mCRC patients who underwent anti-EGFR therapy between October 2017 and October 2018 were analyzed retrospectively. A total of 111 patients were included in this study. The survival results showed that gender, age, body mass index, primary tumor site, and recurrence did not significantly affect OS and PFS. However, the first-line anti-EGFR inhibitor treatment was significantly associated with OS (p < 0.001) and PFS (p < 0.001). There was no significant difference in the incidence of acne between males and females in grades 1 and 2, while males have a greater risk in grades 3 and 4 than females (20.3 vs. 4.8%; p-value = 0.041). Skin toxicity was not a predictor of anti-EGFR treatment response in this investigation.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
    Pietrantonio, Filippo
    Vernieri, Claudio
    Siravegna, Giulia
    Mennitto, Alessia
    Berenato, Rosa
    Perrone, Federica
    Gloghini, Annunziata
    Tamborini, Elena
    Lonardi, Sara
    Morano, Federica
    Picciani, Benedetta
    Busico, Adele
    Volpi, Chiara Costanza
    Martinetti, Antonia
    Battaglin, Francesca
    Bossi, Ilaria
    Pellegrinelli, Alessio
    Milione, Massimo
    Cremolini, Chiara
    Di Bartolomeo, Maria
    Bardelli, Alberto
    de Braud, Filippo
    CLINICAL CANCER RESEARCH, 2017, 23 (10) : 2414 - 2422
  • [22] Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
    Zlobec, Inti
    Molinari, Francesca
    Martin, Vittoria
    Mazzucchelli, Luca
    Saletti, Piercarlo
    Trezzi, Rosangela
    De Dosso, Sara
    Vlajnic, Tatjana
    Frattini, Milo
    Lugli, Alessandro
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (38) : 4823 - 4831
  • [23] Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
    Inti Zlobec
    Francesca Molinari
    Vittoria Martin
    Luca Mazzucchelli
    Piercarlo Saletti
    Rosangela Trezzi
    Sara De Dosso
    Tatjana Vlajnic
    Milo Frattini
    Alessandro Lugli
    World Journal of Gastroenterology, 2010, 16 (38) : 4823 - 4831
  • [24] Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
    Lacouture, Mario E.
    Anadkat, Milan
    Jatoi, Aminah
    Garawin, Tamer
    Bohac, Chet
    Mitchell, Edith
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : 85 - 96
  • [25] Use of anti-EGFR agents among elderly patients with metastatic colorectal cancer (mCRC).
    D'Silva, Ashley James
    Dotan, Efrat
    Kloth, Dwight D.
    Beck, Andrew
    Cohen, Steven J.
    Denlinger, Crystal Shereen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [26] Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
    Cremolini, Chiara
    Montagut, Clara
    Ronga, Philippe
    Venturini, Filippo
    Yamaguchi, Kensei
    Stintzing, Sebastian
    Sobrero, Alberto
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [27] Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer
    Annunziata, Maria Carmela
    De Stefano, Alfonso
    Fabbrocini, Gabriella
    Leo, Silvana
    Marchetti, Paolo
    Romano, Maria Concetta
    Romano, Ivana
    CLINICAL DRUG INVESTIGATION, 2019, 39 (09) : 825 - 834
  • [28] Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer
    Maria Carmela Annunziata
    Alfonso De Stefano
    Gabriella Fabbrocini
    Silvana Leo
    Paolo Marchetti
    Maria Concetta Romano
    Ivana Romano
    Clinical Drug Investigation, 2019, 39 : 825 - 834
  • [29] Consensus recommendations for the use of anti-EGFR therapies in metastatic colorectal cancer
    Cripps, C.
    Gill, S.
    Ahmed, S.
    Colwell, B.
    Dowden, S.
    Kennecke, H.
    Maroun, J.
    Samson, B.
    Thirlwell, M.
    Wong, R.
    CURRENT ONCOLOGY, 2010, 17 (06) : 272 - 278
  • [30] Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
    F Di Fiore
    R Sesboüé
    P Michel
    J C Sabourin
    T Frebourg
    British Journal of Cancer, 2010, 103 : 1765 - 1772